As dean of the UNC School of Medicine and CEO of UNC Health Care, I have the fortune of working alongside some of the best and brightest minds in health care. Through research, innovation and advanced health care delivery, they are responsible for tackling some of our most pressing health care challenges.
For instance, for the first time, a global research effort led by John Buse, MD, PhD, professor of medicine at the UNC School of Medicine and director of the UNC Diabetes Center, determined that a new Type 2 diabetes therapy proves better than traditional insulin injections.
The drug IDegLira proved to be more effective than basal insulin glargine injections at reducing the average amount of blood sugar over the course of several months. The new therapy was also associated with weight loss and a substantially lower rate of hypoglycemia – i.e., low blood sugar – compared with more commonly used injections, a major development in the treatment of Type 2 diabetes.
Another area where our researchers are making breakthroughs is in autism and neurodegenerative diseases. Dr. Mark Zylka, PhD, associate professor of cell biology and physiology at UNC, led a team of researchers who published a study on the role that a new class of fungicides could play in autism and neurodegenerative disease. Along with his team, Dr. Zylka found a class of commonly used fungicides that produce gene expression changes similar to those in people with autism and neurodegenerative conditions, including Alzheimer’s disease and Huntington’s disease. The study, published in Nature Communications, describes a new way to home in on chemicals that have the potential to affect brain functions.
This is the kind of research that makes UNC one of the leading academic medical centers in the nation. More importantly, research drives better care and leads to more effective treatments.
For more information on the diabetes study, click here.
For more information on the fungicide study, click here.